Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma

Oncology

Garth William Strohbehn, J.D. Nieto, Daniel A. Goldstein, Alex K. Bryant

29 September 2026·1 min read·JAMA Network Open

Abstract / Summary

This comparative effectiveness research study examines outcomes associated with pembrolizumab and nivolumab among US veterans with advanced, unresectable, or metastatic melanoma.

Topics

Cancer Immunotherapy and BiomarkersOpen access

DOI:10.1001/jamanetworkopen.2026.36432

Primary Source

JAMA Network Open

View Source

Loading your page…

Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma

Abstract / Summary

Topics

Pembrolizumab vs Nivolumab as Initial Treatment for Advanced, Unresectable, or Metastatic Melanoma

Abstract / Summary

Topics

Related Clinical Guidelines